|
NZ563263A
(en)
|
2005-05-17 |
2010-04-30 |
Univ Connecticut |
Composition and methods for immunomodulation in an organism
|
|
HUE037464T2
(hu)
|
2005-12-02 |
2018-08-28 |
Icahn School Med Mount Sinai |
Nem-natív felületi fehérjéket prezentáló kiméra Newcastle disease vírusok és alkalmazásuk
|
|
CA2636111C
(en)
|
2006-01-13 |
2018-04-03 |
The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health |
Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells
|
|
DK2388266T3
(da)
|
2007-05-11 |
2014-05-26 |
Altor Bioscience Corp |
Fusionsmolekyler og IL-15-varianter
|
|
EP2724727A1
(en)
|
2007-06-27 |
2014-04-30 |
The United States of America, as Represented by The Secretary, Department of Health and Human Services |
Complexes of IL-15 and IL-15R alpha and uses thereof
|
|
WO2018112219A1
(en)
*
|
2016-12-14 |
2018-06-21 |
Nant Holdings Ip, Llc |
Superkine
|
|
CN105017429B
(zh)
|
2010-09-21 |
2021-04-06 |
阿尔托生物科学有限公司 |
多聚体il-15可溶性融合分子与其制造与使用方法
|
|
US11053299B2
(en)
|
2010-09-21 |
2021-07-06 |
Immunity Bio, Inc. |
Superkine
|
|
PT2663579T
(pt)
|
2011-01-14 |
2017-07-28 |
Univ California |
Terapêutica de anticorpos contra a proteína r0r-1 e métodos para sua utilização
|
|
RS57369B1
(sr)
*
|
2012-06-08 |
2018-08-31 |
Alkermes Inc |
Ligandi modifikovani cirkularnom permutacijom kao agonisti i antagonisti
|
|
CA2888896A1
(en)
|
2012-10-24 |
2014-05-01 |
Admune Therapeutics Llc |
Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
|
|
KR102208505B1
(ko)
*
|
2012-12-11 |
2021-01-27 |
앨버트 아인슈타인 컬리지 오브 메디신 |
고처리량 수용체:리간드 확인을 위한 방법
|
|
WO2014158811A1
(en)
|
2013-03-14 |
2014-10-02 |
Icahn School Of Medicine At Mount Sinai |
Newcastle disease viruses and uses thereof
|
|
JP2016518361A
(ja)
|
2013-04-19 |
2016-06-23 |
シーチューヌ ファルマＣｙｔｕｎｅ Ｐｈａｒｍａ |
血管漏出症候群の発生を抑制するサイトカイン治療
|
|
KR102452767B1
(ko)
|
2013-05-14 |
2022-10-12 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
가공된 키메라 항원 수용체 (ｃａｒ) ｔ-세포의 인간 적용
|
|
DK3444271T3
(da)
|
2013-08-08 |
2022-01-10 |
Cytune Pharma |
Il-15- og il-15r-alfa-sushi-domænebaserede modulokiner
|
|
KR102861895B1
(ko)
*
|
2013-08-08 |
2025-09-22 |
싸이튠 파마 |
병용 약학 조성물
|
|
EP3049114B1
(en)
|
2013-09-27 |
2021-11-10 |
Massachusetts Institute of Technology |
Carrier-free biologically-active protein nanostructures
|
|
US10206980B2
(en)
*
|
2014-01-08 |
2019-02-19 |
Shanghai Hengrui Pharmaceutical Co., Ltd. |
IL-15 heterodimeric protein and uses thereof
|
|
SI3094351T1
(sl)
|
2014-01-15 |
2022-05-31 |
Kadmon Corporation, Llc |
Imunomodulatorna sredstva
|
|
EP3105335B1
(en)
|
2014-02-14 |
2019-10-02 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptors and methods of making
|
|
JP6857498B2
(ja)
|
2014-02-27 |
2021-04-14 |
メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． |
癌を処置するための併用方法
|
|
EP2915569A1
(en)
*
|
2014-03-03 |
2015-09-09 |
Cytune Pharma |
IL-15/IL-15Ralpha based conjugates purification method
|
|
US10464982B2
(en)
|
2014-04-23 |
2019-11-05 |
Emory University |
Compositions of GM-CSF and interleukin fusions for immune modulation and uses related thereto
|
|
KR20210014210A
(ko)
*
|
2014-05-15 |
2021-02-08 |
내셔널 유니버시티 오브 싱가포르 |
변형된 천연 살해 세포 및 그의 용도
|
|
WO2016004060A2
(en)
*
|
2014-06-30 |
2016-01-07 |
Altor Bioscience Corporation |
Il-15-based molecules and methods of use thereof
|
|
EP3174974B1
(en)
|
2014-07-29 |
2020-05-20 |
Novartis AG |
Il-15 and il-15ralpha heterodimer dose escalation regimens for treating conditions
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
ES2952717T3
(es)
|
2014-10-14 |
2023-11-03 |
Novartis Ag |
Moléculas de anticuerpos contra PD-L1 y usos de las mismas
|
|
US10501553B2
(en)
|
2014-11-19 |
2019-12-10 |
Memorial Sloan-Kettering Cancer Center |
Methods and compositions for cancer treating conditions relating to over expressions of EphA2
|
|
RS60996B1
(sr)
*
|
2014-12-19 |
2020-11-30 |
Jiangsu hengrui medicine co ltd |
Interleukin 15 proteinski kompleks i njegova upotreba
|
|
CN104830884A
(zh)
*
|
2015-01-22 |
2015-08-12 |
苏州大学 |
一种携带IL-15/sIL-15Ra融合基因的微环DNA表达载体的构建方法
|
|
EP3064507A1
(en)
|
2015-03-06 |
2016-09-07 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
|
|
CN106380521B
(zh)
|
2015-07-02 |
2020-12-29 |
博际生物医药科技(杭州)有限公司 |
用于肿瘤靶向治疗的白细胞介素-15融合蛋白
|
|
EP3878465A1
(en)
|
2015-07-29 |
2021-09-15 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
|
PT3317301T
(pt)
|
2015-07-29 |
2021-07-09 |
Novartis Ag |
Terapias de associação compreendendo moléculas de anticorpo contra lag-3
|
|
JP6878405B2
(ja)
|
2015-07-29 |
2021-05-26 |
ノバルティス アーゲー |
Ｐｄ−１に対する抗体分子を含む組み合わせ治療
|
|
CN116212048A
(zh)
*
|
2015-08-12 |
2023-06-06 |
麻省理工学院 |
纳米颗粒的细胞表面偶联
|
|
EP3352779A4
(en)
*
|
2015-09-25 |
2020-02-19 |
Altor BioScience Corporation |
INTERLEUKIN-15-SUPERAGONIST FOR SIGNIFICANT REINFORCEMENT OF TRANSPLANT AGAINST TUMOR ACTIVITY
|
|
RU2770001C2
(ru)
*
|
2015-10-06 |
2022-04-14 |
Риджентс Оф Дзе Юниверсити Оф Миннесота |
Терапевтические соединения и способы
|
|
JP2019503349A
(ja)
|
2015-12-17 |
2019-02-07 |
ノバルティス アーゲー |
Ｐｄ−１に対する抗体分子およびその使用
|
|
AU2017219901B2
(en)
|
2016-02-19 |
2022-07-14 |
Nant Holdings Ip, Llc |
Methods of immunogenic modulation
|
|
JP7071288B2
(ja)
|
2016-05-18 |
2022-05-18 |
キュー バイオファーマ， インコーポレイテッド |
Ｔ細胞調節多量体ポリペプチド及びその使用方法
|
|
US11339201B2
(en)
|
2016-05-18 |
2022-05-24 |
Albert Einstein College Of Medicine |
Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
|
|
WO2017201352A1
(en)
*
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Mrna combination therapy for the treatment of cancer
|
|
AU2017271593B2
(en)
*
|
2016-05-27 |
2021-04-22 |
Altor Bioscience Corporation |
Construction and characterization of multimeric IL-15-based molecules with CD3 binding domains
|
|
EP3468581A1
(en)
*
|
2016-06-13 |
2019-04-17 |
Torque Therapeutics, Inc. |
Methods and compositions for promoting immune cell function
|
|
EP3484284A1
(en)
*
|
2016-07-12 |
2019-05-22 |
Kymab Limited |
Animals, cells, ligands, polypeptides & methods
|
|
WO2018058067A1
(en)
*
|
2016-09-23 |
2018-03-29 |
The Regents Of The University Of California |
Autologous irradiated whole cell tumor vaccines lentivirally engineered to express cd80, il-15 and il-15 receptor alpha
|
|
KR102562519B1
(ko)
*
|
2016-10-14 |
2023-08-02 |
젠코어 인코포레이티드 |
IL-15/IL-15Rα FC-융합 단백질 및 PD-1 항체 단편을 포함하는 이중특이성 이종이량체 융합 단백질
|
|
JP7213180B2
(ja)
*
|
2016-10-19 |
2023-01-26 |
エフ．ホフマン－ラ ロシュ アーゲー |
免疫コンジュゲートを製造するための方法
|
|
WO2018075989A1
(en)
*
|
2016-10-21 |
2018-04-26 |
Altor Bioscience Corporation |
Multimeric il-15-based molecules
|
|
US20190352363A1
(en)
|
2016-12-22 |
2019-11-21 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
CN108250302A
(zh)
*
|
2016-12-29 |
2018-07-06 |
天津天锐生物科技有限公司 |
一种多功能蛋白质
|
|
CN108250301A
(zh)
*
|
2016-12-29 |
2018-07-06 |
天津天锐生物科技有限公司 |
一种多靶点嵌合抗原受体
|
|
EP3565829A4
(en)
|
2017-01-09 |
2021-01-27 |
Cue Biopharma, Inc. |
T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF
|
|
CN110177568A
(zh)
|
2017-01-20 |
2019-08-27 |
诺华股份有限公司 |
用于治疗癌症的组合疗法
|
|
US20200237874A1
(en)
|
2017-01-20 |
2020-07-30 |
Novartis Ag |
Combination therapy for the treatment of cancer
|
|
CA3055318C
(en)
|
2017-03-06 |
2025-11-25 |
Altor Bioscience Corporation |
IL-15-BASED FUSION PROTEINS SPECIFIC TO IL-12 AND IL-18
|
|
IL309479A
(en)
|
2017-03-15 |
2024-02-01 |
Cue Biopharma Inc |
Methods for modulating an immune response
|
|
IL269553B2
(en)
|
2017-03-27 |
2025-10-01 |
Nat Univ Singapore |
Truncated NKG2D chimeric receptors and their uses in immunotherapy with natural killer cells
|
|
BR112019020001A2
(pt)
|
2017-03-27 |
2020-04-28 |
Nat Univ Singapore |
linhagens celulares estimuladoras para expansão ex vivo e ativação de células exterminadoras naturais
|
|
US20190048055A1
(en)
*
|
2017-03-31 |
2019-02-14 |
Altor Bioscience Corporation |
Alt-803 in combination with anti-cd38 antibody for cancer therapies
|
|
JOP20190256A1
(ar)
|
2017-05-12 |
2019-10-28 |
Icahn School Med Mount Sinai |
فيروسات داء نيوكاسل واستخداماتها
|
|
WO2018229706A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Combination therapy for the treatment of cancer
|
|
WO2018236890A1
(en)
|
2017-06-20 |
2018-12-27 |
Nantkwest, Inc. |
Nk-92 cells and il-15 agonist combination therapy
|
|
JP2020524512A
(ja)
|
2017-06-21 |
2020-08-20 |
アイセル・ジーン・セラピューティクス・エルエルシー |
キメラ抗体受容体（ＣＡＲｓ）の組成物およびその使用方法
|
|
EP3645122A1
(en)
|
2017-06-30 |
2020-05-06 |
Xencor, Inc. |
Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains
|
|
JP2020530440A
(ja)
|
2017-07-03 |
2020-10-22 |
トルク セラピューティクス， インコーポレイテッド |
免疫刺激性融合分子をコードするポリヌクレオチドおよびその使用
|
|
CA3070016A1
(en)
|
2017-07-25 |
2019-01-31 |
Jiangsu Hengrui Medicine Co., Ltd. |
Il-15 protein complex pharmaceutical composition and uses thereof
|
|
KR20200090742A
(ko)
|
2017-08-28 |
2020-07-29 |
알토 바이오사이언스 엘엘씨 |
Il-7 및 il-21에의 il-15 기반 융합
|
|
US11524033B2
(en)
|
2017-09-05 |
2022-12-13 |
Torque Therapeutics, Inc. |
Therapeutic protein compositions and methods of making and using the same
|
|
CN111247168B
(zh)
|
2017-10-12 |
2023-12-29 |
美商生物细胞基因治疗有限公司 |
靶向多种抗原的复合嵌合抗原受体(cCAR)及其组成和使用方法
|
|
CN109705211B
(zh)
|
2017-10-26 |
2020-08-18 |
苏州复融生物技术有限公司 |
一种IgG1 Fc单体及其应用
|
|
JP2021504413A
(ja)
|
2017-12-01 |
2021-02-15 |
メルス ナムローゼ フェンノートシャップ |
組み合わせ治療のための二重特異性抗体及びｉｌ−１５の使用
|
|
WO2019126240A1
(en)
*
|
2017-12-19 |
2019-06-27 |
Blaze Bioscience, Inc. |
Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof
|
|
WO2019135958A2
(en)
|
2018-01-05 |
2019-07-11 |
Oleg Shikhman |
Surgical clip and deployment system
|
|
WO2019139896A1
(en)
|
2018-01-09 |
2019-07-18 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
EP3746104A1
(en)
|
2018-02-02 |
2020-12-09 |
Novartis AG |
Combination of sting agonist and il-15/il15-ra for the treatment of cancer
|
|
JP7360174B2
(ja)
|
2018-02-09 |
2023-10-12 |
ナショナル ユニヴァーシティー オブ シンガポール |
ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用
|
|
MA52426A
(fr)
*
|
2018-02-26 |
2021-06-02 |
Synthorx Inc |
Conjugués d'il-15 et leurs utilisations
|
|
EP3759129A1
(en)
|
2018-02-28 |
2021-01-06 |
Pfizer Inc |
Il-15 variants and uses thereof
|
|
US11168138B2
(en)
|
2018-03-26 |
2021-11-09 |
Altor Bioscience, Llc |
Anti-PDL1, IL-15 and TGF-beta receptor combination molecules
|
|
JP7334985B2
(ja)
|
2018-04-02 |
2023-08-29 |
ナショナル ユニヴァーシティー オブ シンガポール |
免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和
|
|
WO2019195420A1
(en)
|
2018-04-04 |
2019-10-10 |
Nant Holding IP, LLC |
Advanced avartar dendritic cells
|
|
KR20210003170A
(ko)
|
2018-04-18 |
2021-01-11 |
젠코어 인코포레이티드 |
IL-15/IL-15Rα 이종이량체 Fc 융합 단백질 및 이의 용도
|
|
CA3097741A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
|
|
WO2019204646A1
(en)
*
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains
|
|
AU2019256539A1
(en)
|
2018-04-18 |
2020-11-26 |
Xencor, Inc. |
PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
|
|
EP3849299A1
(en)
*
|
2018-04-26 |
2021-07-21 |
F. Hoffmann-La Roche AG |
Method of and system for tracking an animal in a population of animals
|
|
CN110437339B
(zh)
*
|
2018-05-04 |
2021-08-13 |
免疫靶向有限公司 |
一种以白介素15为活性成分的融合蛋白型药物前体
|
|
US20220403001A1
(en)
|
2018-06-12 |
2022-12-22 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
WO2019246563A1
(en)
*
|
2018-06-22 |
2019-12-26 |
Kite Pharma, Inc. |
Chimeric transmembrane proteins and uses thereof
|
|
CN120424233A
(zh)
|
2018-06-22 |
2025-08-05 |
科优基因公司 |
基于细胞因子的可生物活化药物及其使用方法
|
|
JP7440102B2
(ja)
*
|
2018-06-22 |
2024-02-28 |
キュージーン インコーポレイテッド |
新規インターロイキン－１５（ｉｌ－１５）融合タンパク質およびその使用
|
|
WO2020023713A1
(en)
*
|
2018-07-26 |
2020-01-30 |
Nantbio, Inc. |
Tri-cytokine txm compositions and methods
|
|
EP3831945A4
(en)
*
|
2018-07-30 |
2022-05-04 |
Jinyu Zhang |
PROTEIN HETERODIMER AND ITS USE
|
|
US12350316B2
(en)
|
2018-08-16 |
2025-07-08 |
Nantbio, Inc. |
IL7-IL 15 TxM compositions and methods
|
|
WO2020037215A1
(en)
|
2018-08-17 |
2020-02-20 |
Icahn School Of Medicine At Mount Sinai |
Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
|
|
AU2019330347B2
(en)
|
2018-08-29 |
2025-07-24 |
National University Of Singapore |
A method to specifically stimulate survival and expansion of genetically-modified immune cells
|
|
EP4659757A3
(en)
|
2018-08-30 |
2026-01-14 |
ImmunityBio, Inc. |
Multi-chain chimeric polypeptides and uses thereof
|
|
AU2019328575B2
(en)
|
2018-08-30 |
2024-07-11 |
Immunitybio, Inc. |
Single-chain and multi-chain chimeric polypeptides and uses thereof
|
|
EP3843788A1
(en)
|
2018-08-30 |
2021-07-07 |
HCW Biologics, Inc. |
Single-chain chimeric polypeptides and uses thereof
|
|
JP7479383B2
(ja)
|
2018-09-27 |
2024-05-08 |
エクシリオ デベロップメント， インコーポレイテッド |
マスクされたサイトカインポリペプチド
|
|
US11701408B2
(en)
*
|
2018-10-11 |
2023-07-18 |
Nantcell, Inc. |
Treatment of immunosuppressed subjects
|
|
PE20211055A1
(es)
|
2018-10-12 |
2021-06-07 |
Xencor Inc |
Proteinas de fusion il-15 / il-15 ralpha f c dirigidas a pd-1 y usos en terapias de combinacion de las mismas
|
|
CA3114707A1
(en)
|
2018-10-19 |
2020-04-23 |
Regents Of The University Of Minnesota |
Nk engager molecules and methods of use thereof
|
|
WO2020097395A1
(en)
|
2018-11-08 |
2020-05-14 |
The Regents Of The University Of California |
Systems and methods for targeting cancer cells
|
|
CA3122333A1
(en)
|
2018-12-13 |
2020-06-18 |
Jiangsu Hengrui Medicine Co., Ltd. |
Use of il-15 protein complex joint pd-l1 antibody for treating tumor diseases
|
|
US11618776B2
(en)
|
2018-12-20 |
2023-04-04 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains
|
|
CN114344461A
(zh)
|
2018-12-20 |
2022-04-15 |
美勒斯公司 |
用于治疗疾病的CLEC12AxCD3双特异性抗体和方法
|
|
WO2020146835A1
(en)
|
2019-01-11 |
2020-07-16 |
Memorial Sloan Kettering Cancer Center |
Multimerization of il-15/il-15r-alpha-fc complexes to enhance immunotherapy
|
|
US12325734B2
(en)
|
2019-01-15 |
2025-06-10 |
Altor Bioscience Llc |
Human immunodeficiency virus-specific T cell receptors
|
|
WO2020180882A1
(en)
|
2019-03-05 |
2020-09-10 |
Nkarta, Inc. |
Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
|
|
US20220218789A1
(en)
|
2019-05-10 |
2022-07-14 |
Nant Holdings Ip, Llc |
Nogapendekin Alfa-Inbakicept For Immune Stimulant Therapies And Treatment Of Viral Infections
|
|
US12085571B2
(en)
|
2019-06-13 |
2024-09-10 |
Immunitybio, Inc. |
Biological deposit labeling and tracking including isotope, rare earth metal or mitochondria tags
|
|
KR20220035394A
(ko)
|
2019-06-21 |
2022-03-22 |
에이치씨더블유 바이올로직스, 인크. |
다중-사슬 키메라 폴리펩티드 및 이의 용도
|
|
US11453862B2
(en)
|
2019-07-08 |
2022-09-27 |
Immunitybio, Inc. |
Mononuclear cell derived NK cells
|
|
EP3853354A4
(en)
|
2019-07-08 |
2022-04-20 |
ImmunityBio, Inc. |
NK CELLS DERIVED FROM MONONUCLEAR CELLS
|
|
US11364291B1
(en)
*
|
2019-07-18 |
2022-06-21 |
Nantcell, Inc. |
Bacillus Calmette-Guerin (BCG) and antigen presenting cells for treatment of bladder cancer
|
|
CN110478474B
(zh)
*
|
2019-08-21 |
2020-06-02 |
启辰生生物科技(珠海)有限公司 |
免疫调节剂、疫苗、细胞及应用
|
|
EP4021928A4
(en)
*
|
2019-08-29 |
2023-09-20 |
NantBio, Inc. |
MODIFIED N-810 AND ASSOCIATED METHODS
|
|
US20230092895A1
(en)
|
2019-08-30 |
2023-03-23 |
Obsidian Therapeutics, Inc. |
Tandem cd19 car-based compositions and methods for immunotherapy
|
|
RU2753282C2
(ru)
*
|
2019-09-19 |
2021-08-12 |
Закрытое Акционерное Общество "Биокад" |
ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ
|
|
TW202128757A
(zh)
|
2019-10-11 |
2021-08-01 |
美商建南德克公司 |
具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
|
|
WO2021113577A1
(en)
*
|
2019-12-05 |
2021-06-10 |
Immune Targeting Inc. |
Interleukin 15 fusion proteins and prodrugs, and compositions and methods thereof
|
|
CN113135996A
(zh)
*
|
2019-12-09 |
2021-07-20 |
启愈生物技术(上海)有限公司 |
一种双特异抗体及其应用
|
|
CA3165514A1
(en)
*
|
2019-12-31 |
2021-07-08 |
Navrogen, Inc. |
Composition and use of engineered anti-cd20 monoclonal antibodies refactory to tumor immune-suppressive factor ca125/muc16
|
|
US20230056856A1
(en)
|
2020-01-08 |
2023-02-23 |
Obsidian Therapeutics, Inc. |
Compositions and methods for tunable regulation of transcription
|
|
WO2021142476A1
(en)
|
2020-01-12 |
2021-07-15 |
Dragonfly Therapeutics, Inc. |
Single-chain polypeptides
|
|
WO2021155181A1
(en)
*
|
2020-01-31 |
2021-08-05 |
Auragent Bioscience, Llc |
Ultrabright fluorescent nanocomposite structures for enhanced fluorescent bioassays
|
|
JP2022522566A
(ja)
*
|
2020-02-05 |
2022-04-20 |
ノバルティス アーゲー |
ＣＨＯ細胞で発現されたｈｅｔ ＩＬ－１５
|
|
AU2021220870A1
(en)
|
2020-02-11 |
2022-08-04 |
Immunitybio, Inc. |
Methods of treating age-related and inflammatory diseases
|
|
EP4103600A1
(en)
|
2020-02-11 |
2022-12-21 |
HCW Biologics, Inc. |
Chromatography resin and uses thereof
|
|
IL295083A
(en)
|
2020-02-11 |
2022-09-01 |
Hcw Biologics Inc |
Methods for activating regulatory t cells
|
|
CN115244077B
(zh)
|
2020-03-11 |
2025-04-29 |
南特细胞公司 |
蛋白质治疗剂
|
|
WO2021202354A1
(en)
*
|
2020-03-30 |
2021-10-07 |
Proviva Therapeutics (Hong Kong) Limited |
Il-2/il-15 compositions and methods of use thereof
|
|
BR112022020973A2
(pt)
|
2020-04-22 |
2022-12-06 |
Novartis Ag |
Composições farmacêuticas e produtos farmacêuticos de interleucina-15 humana heterodimérica (hetil-15)
|
|
AU2021262794A1
(en)
|
2020-04-29 |
2022-11-24 |
Immunitybio, Inc. |
Anti-CD26 proteins and uses thereof
|
|
CA3169949A1
(en)
|
2020-05-12 |
2021-11-18 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
US11318189B1
(en)
|
2020-05-13 |
2022-05-03 |
Nantcell, Inc. |
IL-15 agonist drug combinations for immune therapy
|
|
US12024545B2
(en)
|
2020-06-01 |
2024-07-02 |
HCW Biologics, Inc. |
Methods of treating aging-related disorders
|
|
WO2021253360A1
(en)
*
|
2020-06-18 |
2021-12-23 |
Proviva Therapeutics (Hong Kong) Limited |
Activatable procytokines
|
|
US12252525B2
(en)
|
2020-07-31 |
2025-03-18 |
Nantbio, Inc. |
Chimeric T cell receptors, nucleic acids, and methods of making and using the same
|
|
US20230280356A1
(en)
|
2020-08-03 |
2023-09-07 |
Nantcell, Inc. |
Drug-specific pharmacokinetic assay for il-15 superagonist
|
|
JP2023541366A
(ja)
|
2020-09-09 |
2023-10-02 |
キュー バイオファーマ， インコーポレイテッド |
１型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法
|
|
US20230357344A1
(en)
*
|
2020-09-16 |
2023-11-09 |
Beigene, Ltd. |
Interleukin 15 Constructs and Methods of Use
|
|
US12280120B2
(en)
|
2020-11-25 |
2025-04-22 |
Xilio Development, Inc. |
Tumor-specific cleavable linkers
|
|
US11591381B2
(en)
|
2020-11-30 |
2023-02-28 |
Crispr Therapeutics Ag |
Gene-edited natural killer cells
|
|
KR20230118887A
(ko)
|
2020-12-03 |
2023-08-14 |
센츄리 쎄라퓨틱스 인코포레이티드 |
유전자 조작 세포 및 이의 용도
|
|
US11661459B2
(en)
|
2020-12-03 |
2023-05-30 |
Century Therapeutics, Inc. |
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
|
|
JP2024500847A
(ja)
|
2020-12-18 |
2024-01-10 |
センチュリー セラピューティクス，インコーポレイテッド |
適合可能な受容体特異性を有するキメラ抗原受容体システム
|
|
AU2021410788A1
(en)
*
|
2020-12-23 |
2023-08-03 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
CN113321736B
(zh)
*
|
2020-12-30 |
2024-01-09 |
苏州复融生物技术有限公司 |
一种长效化白介素15融合蛋白及其制备方法和应用
|
|
WO2022144632A1
(en)
|
2020-12-30 |
2022-07-07 |
Crispr Therapeutics Ag |
Compositions and methods for differentiating stem cells into nk cells
|
|
US20240307437A1
(en)
|
2021-01-29 |
2024-09-19 |
Iovance Biotherapeutics, Inc. |
Cytokine associated tumor infiltrating lymphocytes compositions and methods
|
|
MX2023011268A
(es)
|
2021-03-24 |
2023-12-14 |
Alkermes Inc |
Anticuerpos upar y proteínas de fusión con estos.
|
|
WO2022212614A1
(en)
*
|
2021-03-31 |
2022-10-06 |
Anwita Biosciences, Inc. |
Fusion proteins, pharmaceutical compositions, and therapeutic applications
|
|
EP4329887A1
(en)
|
2021-04-28 |
2024-03-06 |
Minotaur Therapeutics, Inc. |
Humanized chimeric bovine antibodies and methods of use
|
|
CN113321740B
(zh)
*
|
2021-05-08 |
2023-07-18 |
上海交通大学 |
一种融合蛋白及其制备方法和用途
|
|
CN118251228A
(zh)
*
|
2021-05-28 |
2024-06-25 |
艾克索生物制药有限公司 |
具有sPD-1和IL-15的双特异性Fc融合蛋白
|
|
WO2022260849A1
(en)
|
2021-06-09 |
2022-12-15 |
Nant Holdings Ip, Llc |
Methods and systems for producing a protein of interest in a plant
|
|
CN113736810B
(zh)
*
|
2021-09-08 |
2024-05-24 |
苏州因特药物研发有限公司 |
构建体、载体、蛋白、细胞、制备方法、产品及应用
|
|
US20240415964A1
(en)
|
2021-11-02 |
2024-12-19 |
Immunitybio, Inc. |
Natural killer cells for chordoma therapy
|
|
WO2023086772A1
(en)
|
2021-11-12 |
2023-05-19 |
Xencor, Inc. |
Bispecific antibodies that bind to b7h3 and nkg2d
|
|
US12297247B2
(en)
|
2022-01-22 |
2025-05-13 |
Nantcell, Inc. |
Fusion molecules of CTLA4 and IL-15
|
|
CN116854821A
(zh)
|
2022-08-15 |
2023-10-10 |
海徕科(北京)生物技术有限公司 |
IL-15突变体-Fc/IL-15Rα亚基-Fc异源二聚体及其用途
|
|
EP4335870A1
(en)
|
2022-09-06 |
2024-03-13 |
NantCell, Inc. |
Peptide therapeutics against sars-cov-2 spike protein
|
|
WO2024102636A1
(en)
|
2022-11-07 |
2024-05-16 |
Xencor, Inc. |
Bispecific antibodies that bind to b7h3 and mica/b
|
|
WO2024118836A1
(en)
|
2022-11-30 |
2024-06-06 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes with shortened rep step
|
|
CN120916753A
(zh)
*
|
2023-03-29 |
2025-11-07 |
星锐医药(苏州)有限公司 |
编码治疗性多肽的核酸及包含所述核酸的脂质纳米颗粒组合物
|
|
CN121240886A
(zh)
*
|
2023-06-06 |
2025-12-30 |
杰科生物医药公司 |
白细胞介素-15融合蛋白及其使用方法
|
|
WO2025010111A1
(en)
*
|
2023-07-05 |
2025-01-09 |
Nanotein Technologies, Inc. |
Cell signaling complexes and uses thereof
|
|
TW202509219A
(zh)
|
2023-07-13 |
2025-03-01 |
美商艾歐凡斯生物治療公司 |
編碼細胞介素之慢病毒載體及其用於製備腫瘤浸潤性淋巴球之用途
|
|
WO2025019077A1
(en)
|
2023-07-18 |
2025-01-23 |
Nanotein Technologies, Inc. |
Reagents, reagent kits, and culture media for activating and expanding immune cells and uses thereof
|
|
WO2025076124A1
(en)
*
|
2023-10-02 |
2025-04-10 |
Immunitybio, Inc. |
Methods of generating, stimulating, or increasing proliferation of different subsets of cd8+ t cells
|
|
WO2025085672A1
(en)
|
2023-10-17 |
2025-04-24 |
Xencor, Inc. |
Bispecific antibodies that bind to nkp46 and mica/b
|
|
US20250134974A1
(en)
*
|
2023-10-31 |
2025-05-01 |
Immunitybio, Inc. |
Multi-chain chimeric polypeptides and use thereof in the treatment of advanced solid tumors
|
|
CN118108809B
(zh)
*
|
2024-03-15 |
2025-02-28 |
西湖实验室(生命科学和生物医学浙江省实验室) |
一种跨膜荧光蛋白、水溶荧光蛋白及其用途
|
|
US20260001951A1
(en)
|
2024-06-28 |
2026-01-01 |
Immunitybio, Inc. |
Anti-SLAMF7 Antibodies And Therapeutics
|
|
WO2026006784A1
(en)
|
2024-06-28 |
2026-01-02 |
Iovance Biotherapeutics, Inc. |
Methods of making tumor reactive peripheral blood lymphocytes (trpbl)
|
|
US20260027155A1
(en)
|
2024-07-23 |
2026-01-29 |
Immunitybio, Inc. |
Compositions and methods related to potent cytotoxic m-cenk cells from cd3/cd14-depleted apheresis products
|